Israel’s Teva is partnering with France’s Sanofi (see also here) to develop and commercialize TEV 574, currently in Phase 2b clinical trials, for the anti-TL1A treatment of ulcerative colitis and Crohn’s Disease, two types of inflammatory bowel disease (IBD).

https://en.globes.co.il/en/article-teva-teams-with-sanofi-on-inflammatory-bowel-treatment-1001459330